Vascular normalization: a real benefit?

被引：13

作者：

Ribatti, Domenico ^{[1
]}

机构：

[1] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2011年 / 68卷 / 02期

关键词：

Angiogenesis; Antiangiogenesis; Chemotherapy; Vascular normalization; VEGF; TUMOR VASCULATURE; BLOOD-VESSELS; ENDOTHELIAL SPROUTS; BASEMENT-MEMBRANE; ANGIOGENESIS; BEVACIZUMAB; PACLITAXEL; THERAPY; ABNORMALITIES; OXYGENATION;

D O I：

10.1007/s00280-011-1683-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. In this review article, it has been analyzed whether the so-called vascular normalization of abnormal tumor blood vessels as an effect of VEGF inhibition in association with chemotherapeutic agents in the treatment of tumors produces a real benefit. Literature data show that the process of normalization of the structure of tumor blood vessels is not always accompanied with a real benefit. In fact as in the case of cerebral tumors, the process of normalization may induce a re-establishment of the low permeability characteristics of normal brain microvasculature, preventing the delivery of chemotherapeutics.

引用

页码：275 / 278

页数：4

共 41 条

[1] Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors [J].

Baluk, P ;

Morikawa, S ;

Haskell, A ;

Mancuso, M ;

McDonald, DM .

AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05) :1801-1815

[2] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[3] Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma [J].

Batchelor, Tracy T. ;

Duda, Dan G. ;

di Tomaso, Emmanuelle ;

Ancukiewicz, Marek ;

Plotkin, Scott R. ;

Gerstner, Elizabeth ;

Eichler, April F. ;

Drappatz, Jan ;

Hochberg, Fred H. ;

Benner, Thomas ;

Louis, David N. ;

Cohen, Kenneth S. ;

Chea, Houng ;

Exarhopoulos, Alexis ;

Loeffler, Jay S. ;

Moses, Marsha A. ;

Ivy, Percy ;

Sorensen, A. Gregory ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) :2817-2823

[4] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[5] Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas [J].

Chae, Sung-Suk ;

Kamoun, Walid S. ;

Farrar, Christian T. ;

Kirkpatrick, Nathaniel D. ;

Niemeyer, Elisabeth ;

de Graaf, Annemarie M. A. ;

Sorensen, A. Gregory ;

Munn, Lance L. ;

Jain, Rakesh K. ;

Fukumura, Dai .

CLINICAL CANCER RESEARCH, 2010, 16 (14) :3618-3627

[6] Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media [J].

Daldrup, H ;

Shames, DM ;

Wendland, M ;

Okuhata, Y ;

Link, TM ;

Rosenau, W ;

Lu, Y ;

Brasch, RC .

AMERICAN JOURNAL OF ROENTGENOLOGY, 1998, 171 (04) :941-949

[7]

De Boer R, 2009, J CLIN ONCOL, V27

[8]

DVORAK HF, 1987, LAB INVEST, V57, P673

[9]

DVORAK HF, 1988, AM J PATHOL, V133, P95

[10]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

← 1 2 3 4 5 →